Bicycle Therapeutics (BCYC) Stock Forecast, Price Target & Predictions
BCYC Stock Forecast
Bicycle Therapeutics stock forecast is as follows: an average price target of $65.33 (represents a 144.32% upside from BCYC’s last price of $26.74) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
BCYC Price Target
The average price target for Bicycle Therapeutics (BCYC) is $65.33 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $76.00 to $55.00. This represents a potential 144.32% upside from BCYC's last price of $26.74.
BCYC Analyst Ratings
According to 8 Wall Street analysts, Bicycle Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BCYC stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bicycle Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $55.00 | $27.02 | 103.55% | 105.68% |
| Oct 07, 2021 | Edward Tenthoff | Piper Sandler | $76.00 | $48.69 | 56.09% | 184.22% |
| Oct 07, 2021 | Anthony Butler | Roth Capital | $65.00 | $48.69 | 33.50% | 143.08% |
The latest Bicycle Therapeutics stock forecast, released on Sep 16, 2024 by Swayampakula Ramakanth from H.C. Wainwright, set a price target of $55.00, which represents a 103.55% increase from the stock price at the time of the forecast ($27.02), and a 105.68% increase from BCYC last price ($26.74).
Bicycle Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $55.00 | $55.00 |
| Last Closing Price | $26.74 | $26.74 | $26.74 |
| Upside/Downside | -100.00% | 105.68% | 105.68% |
In the current month, the average price target of Bicycle Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bicycle Therapeutics's last price of $26.74. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 06, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Sep 06, 2024 | RBC Capital | Buy | Buy | Hold |
| Sep 05, 2024 | RBC Capital | - | Outperform | Initialise |
| Aug 07, 2024 | Oppenheimer | Buy | Buy | Hold |
| Aug 07, 2024 | B. Riley | - | Neutral | Downgrade |
| Jun 03, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Feb 21, 2024 | Wedbush | Buy | Buy | Hold |
| Feb 21, 2024 | Needham | Market Outperform | Market Outperform | Hold |
Bicycle Therapeutics's last stock rating was published by Cowen & Co. on Sep 16, 2024. The company gave BCYC a "Buy" rating, the same as its previous rate.
Bicycle Therapeutics Financial Forecast
Bicycle Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $5.35M | $11.40M | $4.90M | $3.19M | $3.04M | $4.38M | $3.86M | $3.77M | $4.33M | $1.78M | $1.81M | $3.85M | $3.84M | $1.57M | $1.13M | $5.28M | $614.00K | $1.52M |
| Avg Forecast | $6.22M | $6.22M | $6.80M | $6.05M | $6.57M | $6.82M | $6.13M | $6.06M | $6.98M | $12.94M | $5.78M | $3.88M | $3.55M | $5.70M | $3.69M | $4.46M | $5.52M | $5.75M | $2.31M | $1.81M | $3.66M | $2.73M | $2.36M | $3.50M | $1.48M | $1.32M | $1.03M |
| High Forecast | $6.22M | $6.22M | $6.80M | $6.05M | $6.57M | $9.95M | $6.13M | $6.06M | $15.75M | $13.02M | $5.78M | $3.88M | $3.55M | $5.70M | $3.69M | $4.46M | $5.52M | $5.75M | $2.31M | $1.81M | $3.66M | $2.73M | $2.36M | $3.50M | $1.48M | $1.32M | $1.03M |
| Low Forecast | $6.22M | $6.22M | $6.80M | $6.05M | $6.57M | $4.18M | $6.13M | $6.06M | $2.99M | $12.87M | $5.78M | $3.88M | $3.55M | $5.70M | $3.69M | $4.46M | $5.52M | $5.75M | $2.31M | $1.81M | $3.66M | $2.73M | $2.36M | $3.50M | $1.48M | $1.32M | $1.03M |
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.41% | 1.97% | 1.26% | 0.90% | 0.53% | 1.19% | 0.86% | 0.68% | 0.75% | 0.77% | 1.00% | 1.05% | 1.41% | 0.67% | 0.32% | 3.57% | 0.47% | 1.47% |
Bicycle Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $6.98M, with a low forecast of $2.99M, and a high forecast of $15.75M. BCYC's average Quarter revenue forecast represents a 30.48% increase compared to the company's last Quarter revenue of $5.35M (Sep 23).
Bicycle Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-50.80M | $-41.04M | $-38.87M | $-29.57M | $-26.70M | $-26.39M | $-26.63M | $-17.56M | $-13.93M | $-16.91M | $-15.68M | $-16.72M | $-10.27M | $-11.90M | $-11.13M | $-4.27M | $-9.57M | $-9.85M |
| Avg Forecast | $-6.22M | $-6.22M | $-6.80M | $-6.05M | $-6.57M | $-6.82M | $-6.13M | $-6.06M | $-6.98M | $-12.94M | $-5.78M | $-3.88M | $-3.55M | $-5.70M | $-3.69M | $-16.91M | $-5.52M | $-5.75M | $-2.31M | $-15.24M | $-3.66M | $-2.73M | $-2.36M | $-77.38M | $-1.48M | $-1.32M | $-10.95M |
| High Forecast | $-6.22M | $-6.22M | $-6.80M | $-6.05M | $-6.57M | $-4.18M | $-6.13M | $-6.06M | $-2.99M | $-12.87M | $-5.78M | $-3.88M | $-3.55M | $-5.70M | $-3.69M | $-13.53M | $-5.52M | $-5.75M | $-2.31M | $-12.19M | $-3.66M | $-2.73M | $-2.36M | $-61.90M | $-1.48M | $-1.32M | $-8.76M |
| Low Forecast | $-6.22M | $-6.22M | $-6.80M | $-6.05M | $-6.57M | $-9.95M | $-6.13M | $-6.06M | $-15.75M | $-13.02M | $-5.78M | $-3.88M | $-3.55M | $-5.70M | $-3.69M | $-20.29M | $-5.52M | $-5.75M | $-2.31M | $-18.29M | $-3.66M | $-2.73M | $-2.36M | $-92.85M | $-1.48M | $-1.32M | $-13.14M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.93% | 7.11% | 10.03% | 8.32% | 4.68% | 7.16% | 1.57% | 3.18% | 2.42% | 7.33% | 1.03% | 4.57% | 3.77% | 5.04% | 0.14% | 2.89% | 7.25% | 0.90% |
undefined analysts predict BCYC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bicycle Therapeutics's previous annual EBITDA (undefined) of $NaN.
Bicycle Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | $-49.90M | $-42.60M | $-39.06M | $-29.98M | $-28.35M | $-26.83M | $-27.56M | $-18.04M | $-14.68M | $-17.91M | $-16.19M | $-17.43M | $-10.14M | $-12.12M | $-11.32M | $-4.41M | $-9.48M | $-10.22M |
| Avg Forecast | $-52.10M | $-51.68M | $-47.31M | $-47.57M | $-48.65M | $-41.42M | $-57.59M | $-65.04M | $-64.13M | $-62.43M | $-62.38M | $-56.04M | $-55.05M | $-46.79M | $-44.12M | $-17.43M | $-32.00M | $-31.77M | $-36.97M | $-15.73M | $-24.57M | $-26.91M | $-24.73M | $-78.75M | $-27.24M | $-30.03M | $-11.35M |
| High Forecast | $-52.10M | $-51.68M | $-47.31M | $-47.57M | $-48.65M | $-28.67M | $-57.59M | $-65.04M | $-34.93M | $-12.27M | $-62.38M | $-56.04M | $-55.05M | $-46.79M | $-44.12M | $-13.94M | $-32.00M | $-31.77M | $-36.97M | $-12.59M | $-24.57M | $-26.91M | $-24.73M | $-63.00M | $-27.24M | $-30.03M | $-9.08M |
| Low Forecast | $-52.10M | $-51.68M | $-47.31M | $-47.57M | $-48.65M | $-55.75M | $-57.59M | $-65.04M | $-86.02M | $-98.72M | $-62.38M | $-56.04M | $-55.05M | $-46.79M | $-44.12M | $-20.92M | $-32.00M | $-31.77M | $-36.97M | $-18.88M | $-24.57M | $-26.91M | $-24.73M | $-94.50M | $-27.24M | $-30.03M | $-13.62M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.80% | 0.68% | 0.70% | 0.54% | 0.61% | 0.61% | 1.58% | 0.56% | 0.46% | 0.48% | 1.03% | 0.71% | 0.38% | 0.49% | 0.14% | 0.16% | 0.32% | 0.90% |
Bicycle Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BCYC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Bicycle Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | $16.28M | $15.18M | $14.49M | $10.68M | $10.25M | $11.82M | $16.85M | $8.72M | $8.27M | $7.35M | $8.14M | $10.85M | $7.15M | $6.20M | $5.00M | $3.40M | $4.79M | $2.97M |
| Avg Forecast | $15.28M | $15.28M | $16.70M | $14.86M | $16.13M | $16.76M | $15.05M | $14.89M | $17.15M | $31.78M | $14.18M | $9.52M | $8.72M | $14.01M | $9.06M | $10.96M | $13.57M | $14.12M | $5.67M | $4.45M | $8.98M | $6.69M | $5.80M | $8.61M | $3.63M | $3.24M | $2.54M |
| High Forecast | $15.28M | $15.28M | $16.70M | $14.86M | $16.13M | $24.43M | $15.05M | $14.89M | $38.69M | $31.97M | $14.18M | $9.52M | $8.72M | $14.01M | $9.06M | $10.96M | $13.57M | $14.12M | $5.67M | $4.45M | $8.98M | $6.69M | $5.80M | $8.61M | $3.63M | $3.24M | $2.54M |
| Low Forecast | $15.28M | $15.28M | $16.70M | $14.86M | $16.13M | $10.27M | $15.05M | $14.89M | $7.34M | $31.60M | $14.18M | $9.52M | $8.72M | $14.01M | $9.06M | $10.96M | $13.57M | $14.12M | $5.67M | $4.45M | $8.98M | $6.69M | $5.80M | $8.61M | $3.63M | $3.24M | $2.54M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.51% | 1.07% | 1.52% | 1.22% | 0.73% | 1.31% | 1.54% | 0.64% | 0.59% | 1.30% | 1.83% | 1.21% | 1.07% | 1.07% | 0.58% | 0.93% | 1.48% | 1.17% |
Bicycle Therapeutics's average Quarter SG&A projection for Dec 23 is $17.15M, based on 6 Wall Street analysts, with a range of $7.34M to $38.69M. The forecast indicates a 5.34% rise compared to BCYC last annual SG&A of $16.28M (Sep 23).
Bicycle Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-1.41 | $-1.30 | $-1.01 | $-0.96 | $-0.90 | $-0.93 | $-0.63 | $-0.59 | $-0.74 | $-0.73 | $-0.83 | $-0.52 | $-0.67 | $-0.63 | $-0.25 | $-0.53 | $-1.40 |
| Avg Forecast | $-1.00 | $-0.99 | $-0.91 | $-0.92 | $-0.94 | $-0.80 | $-1.11 | $-1.25 | $-1.23 | $-1.20 | $-1.20 | $-1.08 | $-1.06 | $-0.90 | $-0.85 | $-0.68 | $-0.62 | $-0.61 | $-0.71 | $-0.71 | $-0.47 | $-0.52 | $-0.48 | $-0.37 | $-0.52 | $-0.58 | $-0.46 |
| High Forecast | $-1.00 | $-0.99 | $-0.91 | $-0.92 | $-0.94 | $-0.55 | $-1.11 | $-1.25 | $-0.67 | $-0.24 | $-1.20 | $-1.08 | $-1.06 | $-0.90 | $-0.85 | $-0.68 | $-0.62 | $-0.61 | $-0.71 | $-0.71 | $-0.47 | $-0.52 | $-0.48 | $-0.37 | $-0.52 | $-0.58 | $-0.46 |
| Low Forecast | $-1.00 | $-0.99 | $-0.91 | $-0.92 | $-0.94 | $-1.07 | $-1.11 | $-1.25 | $-1.65 | $-1.90 | $-1.20 | $-1.08 | $-1.06 | $-0.90 | $-0.85 | $-0.68 | $-0.62 | $-0.61 | $-0.71 | $-0.71 | $-0.47 | $-0.52 | $-0.48 | $-0.37 | $-0.52 | $-0.58 | $-0.46 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 1.18% | 1.21% | 0.95% | 1.07% | 1.06% | 1.37% | 1.02% | 0.97% | 1.04% | 1.03% | 1.76% | 1.00% | 1.41% | 1.71% | 0.48% | 0.92% | 3.08% |
According to undefined Wall Street analysts, Bicycle Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BCYC previous annual EPS of $NaN (undefined).
Bicycle Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANEB | Anebulo Pharmaceuticals | $1.83 | $6.00 | 227.87% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| ACRV | Acrivon Therapeutics | $7.87 | $22.00 | 179.54% | Buy |
| BCYC | Bicycle Therapeutics | $26.74 | $65.33 | 144.32% | Buy |
| STOK | Stoke Therapeutics | $13.27 | $30.60 | 130.60% | Buy |
| MLYS | Mineralys Therapeutics | $13.88 | $30.00 | 116.14% | Buy |
| CCCC | C4 Therapeutics | $6.41 | $13.50 | 110.61% | Buy |
| ADAG | Adagene | $2.41 | $5.00 | 107.47% | Buy |
| ORIC | ORIC Pharmaceuticals | $9.15 | $17.00 | 85.79% | Buy |
| CGEM | Cullinan Oncology | $17.37 | $32.00 | 84.23% | Buy |
| KROS | Keros Therapeutics | $61.09 | $102.00 | 66.97% | Buy |
| IDYA | IDEAYA Biosciences | $30.69 | $48.20 | 57.05% | Buy |
| MGTX | MeiraGTx | $5.94 | $9.00 | 51.52% | Buy |
| MRUS | Merus | $51.74 | $77.86 | 50.48% | Buy |
| ANAB | AnaptysBio | $35.18 | $44.80 | 27.35% | Buy |
| IGMS | IGM Biosciences | $16.03 | $20.33 | 26.82% | Buy |
BCYC Forecast FAQ
Is Bicycle Therapeutics a good buy?
Yes, according to 8 Wall Street analysts, Bicycle Therapeutics (BCYC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of BCYC's total ratings.
What is BCYC's price target?
Bicycle Therapeutics (BCYC) average price target is $65.33 with a range of $55 to $76, implying a 144.32% from its last price of $26.74. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bicycle Therapeutics stock go up soon?
According to Wall Street analysts' prediction for BCYC stock, the company can go up by 144.32% (from the last price of $26.74 to the average price target of $65.33), up by 184.22% based on the highest stock price target, and up by 105.68% based on the lowest stock price target.
Can Bicycle Therapeutics stock reach $40?
BCYC's average twelve months analyst stock price target of $65.33 supports the claim that Bicycle Therapeutics can reach $40 in the near future.
What are Bicycle Therapeutics's analysts' financial forecasts?
Bicycle Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $25.58M (high $28.71M, low $22.94M), average EBITDA is $-25.584M (high $-22.942M, low $-28.711M), average net income is $-213M (high $-200M, low $-227M), average SG&A $62.83M (high $70.51M, low $56.34M), and average EPS is $-4.091 (high $-3.846, low $-4.367). BCYC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $25.29M (high $25.29M, low $25.29M), average EBITDA is $-25.291M (high $-25.291M, low $-25.291M), average net income is $-199M (high $-199M, low $-199M), average SG&A $62.11M (high $62.11M, low $62.11M), and average EPS is $-3.821 (high $-3.821, low $-3.821).
Did the BCYC's actual financial results beat the analysts' financial forecasts?
Based on Bicycle Therapeutics's last annual report (Dec 2022), the company's revenue was $14.46M, which missed the average analysts forecast of $17.41M by -16.92%. Apple's EBITDA was $-111M, beating the average prediction of $-29.856M by 271.44%. The company's net income was $-113M, missing the average estimation of $-163M by -31.02%. Apple's SG&A was $49.51M, beating the average forecast of $42.75M by 15.79%. Lastly, the company's EPS was $-3.8, beating the average prediction of $-3.487 by 8.96%. In terms of the last quarterly report (Sep 2023), Bicycle Therapeutics's revenue was $5.35M, missing the average analysts' forecast of $12.94M by -58.65%. The company's EBITDA was $-50.797M, beating the average prediction of $-12.942M by 292.51%. Bicycle Therapeutics's net income was $-49.898M, missing the average estimation of $-62.433M by -20.08%. The company's SG&A was $16.28M, missing the average forecast of $31.78M by -48.77%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.201 by -99.89%